Haili Biotech’s announcement on its wholly-owned subsidiary receiving government subsidies

Securities code: 603718 Securities abbreviation: Haili Biotechnology Announcement number: 2026-011

Shanghai Haili Biotechnology Co., Ltd.

Announcement on Wholly Owned Subsidiaries Obtaining Government Subsidies

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.

1. Basic information on obtaining subsidies

According to the "Shanghai Service Industry Development Guidance Fund Project Implementation Framework Agreement" signed by Shanghai Haili Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), a wholly-owned subsidiary of Shanghai Jiemen Biotechnology Co., Ltd. (hereinafter referred to as "Jiemen Bio") and the Shanghai Jiading District Development and Reform Commission in October 2020, Jiemen Biotechnology received 2,000,000 yuan in district-level matching funds from the People's Government of Waigang Town, Jiading District, Shanghai on March 19, 2026. Since the project has been implemented and accepted, the government subsidies included in the income will account for 1.17% of the company's audited net profit attributable to shareholders of listed companies in 2024. However, according to the company's 2025 annual performance forecast, it is expected to account for more than 10% of the net profits attributable to shareholders of listed companies in 2025.

2. Types of subsidies and their impact on listed companies

According to the relevant provisions of "Accounting Standards for Business Enterprises No. 16 - Government Subsidy", the above-mentioned subsidies are recognized as government subsidies related to income and are expected to have a certain positive impact on the company's operating performance. The above government subsidy data have not been audited. The specific accounting treatment and the impact on the company's profits and losses must be subject to the results of the annual audit and confirmation by the audit agency. Investors are kindly requested to pay attention to investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Haili Biotechnology Co., Ltd.

March 21, 2026